Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)

NCT02352584 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT02352584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)
Lead sponsor
Green Cross Corporation
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
July 31, 2015
Enrollment
1,299 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza